WO2014013505A8 - Amorphous vildagliptin - Google Patents

Amorphous vildagliptin Download PDF

Info

Publication number
WO2014013505A8
WO2014013505A8 PCT/IN2013/000436 IN2013000436W WO2014013505A8 WO 2014013505 A8 WO2014013505 A8 WO 2014013505A8 IN 2013000436 W IN2013000436 W IN 2013000436W WO 2014013505 A8 WO2014013505 A8 WO 2014013505A8
Authority
WO
WIPO (PCT)
Prior art keywords
vildagliptin
preparation
pharmaceutical compositions
provides
present
Prior art date
Application number
PCT/IN2013/000436
Other languages
French (fr)
Other versions
WO2014013505A2 (en
WO2014013505A3 (en
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Dasari Muralidhara Reddy
Kesireddy Subash Chander Reddy
Bandi Vamsi Krishna
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Publication of WO2014013505A2 publication Critical patent/WO2014013505A2/en
Publication of WO2014013505A3 publication Critical patent/WO2014013505A3/en
Publication of WO2014013505A8 publication Critical patent/WO2014013505A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a novel amorphous form of vildagliptin, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides a solid dispersion of vildagliptin in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it. Vildagliptin (LAF237) is an oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs.
PCT/IN2013/000436 2012-07-20 2013-07-16 Amorphous vildagliptin WO2014013505A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ININ2973/CHE/2012 2012-07-20
IN2973CH2012 2012-07-20

Publications (3)

Publication Number Publication Date
WO2014013505A2 WO2014013505A2 (en) 2014-01-23
WO2014013505A3 WO2014013505A3 (en) 2014-03-20
WO2014013505A8 true WO2014013505A8 (en) 2014-09-04

Family

ID=49949320

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2013/000436 WO2014013505A2 (en) 2012-07-20 2013-07-16 Amorphous vildagliptin

Country Status (1)

Country Link
WO (1) WO2014013505A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104644582A (en) * 2014-12-14 2015-05-27 天津市康瑞药业有限公司 Vildagliptin dropping pill and preparation method thereof
WO2022003405A1 (en) 2020-07-03 2022-01-06 Savoi Guilherme One-pot process to obtain a pyrrolidine-2-carbonitrile intermediate compound and industrial scale telescopic process to prepare (2s)-1-[n-(3-hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile (vildagliptin) using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600008A (en) * 2005-01-18 2006-08-09 FORMULATION OF DIRECT COMPRESSION AND PROCESS
BRPI0614610A2 (en) * 2005-08-04 2011-04-05 Novartis Ag compounds
WO2010067233A1 (en) * 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
EA034049B1 (en) * 2009-07-31 2019-12-23 КРКА, д.д., НОВО МЕСТО Granulate comprising vildagliptin, process of preparation thereof and pharmaceutical composition

Also Published As

Publication number Publication date
WO2014013505A2 (en) 2014-01-23
WO2014013505A3 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
WO2009121945A3 (en) Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
MX2012012438A (en) Pharmaceutical formulations comprising pioglitazone and linagliptin.
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
IL233677A (en) Substituted benzisoxazole aminopyrazolo-pyrimidine compounds, pharmaceutical compositions comprising them and use of the compounds for the manufacture of medicaments
WO2014002051A3 (en) Complement pathway modulators and uses thereof
WO2010092090A3 (en) Novel salts of sitagliptin
WO2014002058A3 (en) Complement pathway modulators and uses thereof
AU2012259422A8 (en) Solid forms of a pharmaceutically active substance
EA201200937A1 (en) SOLID MEDICINE FORM TICAGRELOR
WO2009088414A3 (en) Oral pharmaceutical dosage forms
UA106634C2 (en) Solid pharmaceutical dosage form
IL217052A0 (en) Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
WO2012020131A3 (en) Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX359288B (en) Ivabradine hydrochloride form iv.
WO2013004995A8 (en) Pyrimidinone compounds and their use
WO2012174158A3 (en) Administration of benzodiazepine
WO2012016845A3 (en) Pharmaceutical formulation comprising a phosphodiesterase inhibitor
WO2011019326A3 (en) Solubility and stability enchancing pharmaceutical formulation
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
WO2014076712A3 (en) Lurasidone hydrochloride solid dispersion
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
PH12014501408A1 (en) Immediate release multi unit pellet system
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2010049449A3 (en) Novel salts of sunitinib

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13819970

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13819970

Country of ref document: EP

Kind code of ref document: A2